ARTICLE | Finance
New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss
By Selina Koch, Executive Editor, and Gunjan Ohri, Data Content Analyst
December 17, 2024 1:43 AM UTC
Obesity has largely been a big pharma play, but an analysis by BioCentury finds VCs are also seizing opportunities to break into the action, funding at least 21 obesity-focused start-ups since the start of 2021.
Incretins are a major focus of many of these biotechs, but almost all are pursing new targets, either in addition to or instead of incretins. Key avenues for differentiation remain deeper weight loss, muscle preservation, oral administration, durability and tolerability…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654164/obesity-newcos-aim-for-differentiation